# US 2023/0096087 A1 · Prefusion-stabilized herpesvirus glycoprotein-b

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0096087 A1
- Document ID: US20230096087A1
- Status: Published application
- Kind: A1
- Application number: 17/484,583
- Filed: 2021-09-24
- Published: 2023-03-30
- Earliest claimed: 2021-09-24
- Assignees: Heinrich-Pette-Institut, Leibniz-Institut für Experimentelle Virologie
- Applicants: Heinrich-Pette-Institut Leibniz-Institut für Experimentelle Virologie
- Inventors: Kay Grünewald; Benjamin Vollmer
- Web page: https://patentgrep.com/patent/US20230096087A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61P 35/00: Antineoplastic agents
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C07K 2319/00: Fusion polypeptide
- C12N 2710/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16031: Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- C12N 2710/16043: viral genome or elements thereof as genetic vector
- C12N 2710/16622: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16634: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention generally relates to the field of herpesviruses and herpesvirus proteins that can be used for the production of antibodies or therapeutic agents, such as vaccines. More specifically, the present invention relates to a modified herpesvirus glycoprotein B that comprises one or more mutations at defined positions in the primary structure of the protein which retain a stable prefusion conformation which is highly advantageous for the production of antibodies or therapeutic agents, such as vaccines. The invention further relates to nucleic acid molecules which encode such a modified herpesvirus glycoprotein B. The invention further provides methods for producing antibodies or therapeutic agents, such as vaccines, which make use of the modified herpesvirus glycoprotein B or a nucleic acid molecule encoding it. Kits comprising the modified herpesvirus glycoprotein B are provided as well. Finally, the invention also relates to the use of the modified herpesvirus glycoprotein B or a nucleic acid molecule encoding same for drug screening.

## Claims

### Claim 1

A modified herpesvirus envelope glycoprotein-B, wherein the protein comprises a mutation in its amino acid sequence which stabilizes the prefusion confirmation of the protein by preventing the irreversible transition from the metastable prefusion to the postfusion conformation.

### Claim 2 (depends on 1)

The modified herpesvirus envelope glycoprotein-B of claim 1, comprising a mutation of the residue in the position corresponding to position 516 of the unprocessed full-length Herpes simplex virus 1 (HSV-1) envelope glycoprotein-B set forth in SEQ ID NO:1.

### Claim 3 (depends on 2)

The modified herpesvirus glycoprotein-B of claim 2, wherein the residue in the position corresponding to position 516 has been replaced by another amino acid residue.

### Claim 4 (depends on 3)

The modified herpesvirus glycoprotein-B of claim 3, wherein the residue in the position corresponding to position 516 has been replaced by a proline residue.

### Claim 5 (depends on 1)

The modified herpesvirus glycoprotein-B of claim 1, wherein the protein comprises or consists of
(a) the amino acid sequence of any of SEQ ID NO:3, 4, 11, 12, 15, 16, 23, 24, 27, 28, 31, 32, 35 or 36;
(b) an amino acid sequence which has at least 90% identity to the amino acid sequence of SEQ ID NO: 3, 4, 11, 12, 15, 16, 23, 24, 27, 28, 31, 32, 35 or 36;
(c) an immunologically active fragment of any of (a) or (b).

### Claim 6 (depends on 1)

The modified herpesvirus envelope glycoprotein-B of claim 1, comprising a mutation of the Ser residue in the position corresponding to position 392 and a mutation of the Gln residue in the position corresponding to position 532 of the unprocessed full-length Herpes simplex virus 1 (HSV-1) envelope glycoprotein-B set forth in SEQ ID NO: 1.

### Claim 7 (depends on 6)

The modified herpesvirus glycoprotein-B of claim 6, wherein the Ser residue in the position corresponding to position 392 and the Gln residue in the position corresponding to position 532 of the unprocessed full-length Herpes simplex virus 1 (HSV-1) envelope glycoprotein-B have been replaced by a Cys residue.

### Claim 8 (depends on 6)

The modified herpesvirus glycoprotein-B of claim 6, wherein the protein comprises or consists of
(a) the amino acid sequence of SEQ ID NO: 5, 6, 17 or 18;
(b) an amino acid sequence which has at least 90% identity to the amino acid sequence of SEQ ID NO:5, 6, 17 or 18;
(c) an immunologically active fragment of any of (a) or (b).

### Claim 9 (depends on 1)

The modified herpesvirus glycoprotein-B of claim 1, said protein comprising:
(a) a mutation of the His residue in the position corresponding to position 516 of the unprocessed full-length Herpes simplex virus 1 (HSV-1) envelope glycoprotein-B set forth in SEQ ID NO:1, and
(b) a mutation of the Ser residue in the position corresponding to position 392 and a mutation of the Gln residue in the position corresponding to position 532 of the unprocessed full-length Herpes simplex virus 1 (HSV-1) envelope glycoprotein-B set forth in SEQ ID NO: 1.

### Claim 10 (depends on 9)

The modified herpesvirus glycoprotein-B of claim 9, wherein the protein comprises or consists of
(a) the amino acid sequence of SEQ ID NO:7, 8, 19 or 20;
(b) an amino acid sequence which has at least 90% identity to the amino acid sequence of SEQ ID NO:7, 8, 19 or 20;
(c) an immunologically active fragment of any of (a) or (b).

### Claim 11 (depends on 1)

A nucleotide sequence encoding the modified herpesvirus envelope glycoprotein-B of claim 1.

### Claim 12 (depends on 11)

A plasmid comprising the nucleotide sequence of claim 11.

### Claim 13 (depends on 1)

A herpesvirus or recombinant herpesvirus vector comprising the modified herpesvirus envelope glycoprotein-B of claim 1.

### Claim 14 (depends on 13)

The herpesvirus or recombinant herpesvirus vector of claim 13, wherein said herpesvirus or recombinant herpesvirus vector is or is derived from HSV-1 or HSV-2.

### Claim 15 (depends on 1)

A method of treating a herpesvirus infection comprising administering to a subject in need thereof: (a) the modified herpesvirus glycoprotein-B of claim 1; (b) a nucleotide sequence encoding said modified herpesvirus envelope glycoprotein-B; or (c) a herpesvirus or a recombinant herpesvirus vector comprising said modified herpesvirus envelope glycoprotein-B or said nucleotide sequence.

### Claim 16 (depends on 1)

A method of vaccinating a subject against herpesvirus infection comprising administering to a subject in need thereof: (a) the modified herpesvirus glycoprotein-B of claim 1; (b) a nucleotide sequence encoding said modified herpesvirus envelope glycoprotein-B; or (c) a herpesvirus or a recombinant herpesvirus vector comprising said modified herpesvirus envelope glycoprotein-B or said nucleotide sequence.

### Claim 17 (depends on 1)

A cell comprising: (a) the modified herpesvirus glycoprotein-B of claim 1; (b) a nucleotide sequence encoding said modified herpesvirus envelope glycoprotein-B; or (c) a herpesvirus or a recombinant herpesvirus vector comprising said modified herpesvirus envelope glycoprotein-B or said nucleotide sequence.

### Claim 18 (depends on 1)

A pharmaceutical composition or vaccine comprising: (a) the modified herpesvirus glycoprotein-B of claim 1; (b) a nucleotide sequence encoding said modified herpesvirus envelope glycoprotein-B; or (c) a herpesvirus or a recombinant herpesvirus vector comprising said modified herpesvirus envelope glycoprotein-B or said nucleotide sequence.

### Claim 19 (depends on 1)

A method of preparing a vaccine comprising introducing (a) the modified herpesvirus glycoprotein-B of claim 1; (b) a nucleotide sequence encoding said modified herpesvirus envelope glycoprotein-B; or (c) a herpesvirus or a recombinant herpesvirus vector comprising said modified herpesvirus envelope glycoprotein-B or said nucleotide sequence, into a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

A method of screening for an antiviral compound comprising: incubating a candidate compound with (a) the modified herpesvirus glycoprotein-B of claim 1; (b) a nucleotide sequence encoding said modified herpesvirus envelope glycoprotein-B; (c) a herpesvirus or a recombinant herpesvirus vector comprising said modified herpesvirus envelope glycoprotein-B or said nucleotide sequence; or (d) or a cell comprising any of the foregoing (a)-(c) and detecting interaction of said candidate compound therewith, such as its ability to block viral binding.
